I 
118TH CONGRESS 
1ST SESSION H. R. 6424 
To provide additional authorities for the leadership of the United States 
Agency for International Development in health technology innovation 
for global health in low-resource settings, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
NOVEMBER 15, 2023 
Mr. FITZPATRICK (for himself, Ms. HOULAHAN, and Ms. SALAZAR) introduced 
the following bill; which was referred to the Committee on Foreign Affairs 
A BILL 
To provide additional authorities for the leadership of the 
United States Agency for International Development in 
health technology innovation for global health in low- 
resource settings, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Supporting Innovative 
Global Health Technologies Act of 2023’’ or the ‘‘SIGHT 
Act’’. 
SEC. 2. FINDINGS. 
Congress finds the following: 
VerDate Sep 11 2014 
05:22 Nov 30, 2023
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6424.IH
H6424
SSpencer on DSK126QN23PROD with BILLS
(1) The United States Agency for International 
Development has a unique role in the research and 
development of health technologies for global health 
that complements the work of other departments 
and agencies of the United States Government, hav-
ing both an advantage and unique mandate for de-
velopment of health technologies for use in low-re-
source settings. 
(2) It is in the national interest of the United 
States to build greater country capacity for research 
and development of new health technologies in low 
and middle-income countries. 
(3) Investments by the United States Govern-
ment in global health research and development 
should be coordinated with and leverage investments 
from partner country governments, other govern-
ment donors, and the private sector. 
(4) Human immunodeficiency virus, tuber-
culosis, malaria, neglected tropical diseases, emerg-
ing infectious diseases (such as COVID–19, Ebola, 
and Zika), and many other health conditions (such 
as complications in pregnancy) have a dispropor-
tionate public health burden in low- and middle-in-
come countries. 
VerDate Sep 11 2014 
05:22 Nov 30, 2023
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6424.IH
H6424
SSpencer on DSK126QN23PROD with BILLS
(5) Health technologies that were developed for 
use in high-income countries often cannot be imple-
mented in low-resource settings in low- and middle- 
income countries or require adaptation to be effec-
tive. 
(6) Due to poverty or to low incidence, many 
neglected tropical diseases and emerging infectious 
diseases either lack or have limited commercial mar-
kets to drive health technology innovation. 
(7) Achieving the ambitious goals set through 
initiatives such as the President’s Emergency Plan 
for 
AIDS 
Relief 
(commonly 
referred 
to 
as 
‘‘PEPFAR)’’ and the President’s Malaria Initiative 
(commonly referred to as ‘‘PMI’’) will not be pos-
sible without the development and scale-up of new 
health technologies designed for use in low-resource 
settings, which are needed to address both long- 
standing endemic diseases and prepare for potential 
pandemic threats. 
(8) Public funding has proven highly successful 
at incentivizing the development of health tech-
nologies for global health that are high-impact, ac-
cessible, and cost-saving. 
VerDate Sep 11 2014 
05:22 Nov 30, 2023
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6424.IH
H6424
SSpencer on DSK126QN23PROD with BILLS
(9) COVID–19 has demonstrated the impor-
tance of global access to health technologies de-
signed for low-resource settings. 
(10) Support for the development of accessible 
health technologies for low-resource settings can 
have reciprocal value and produce tools that reduce 
health care costs, improve public health, and 
strengthen health security for the United States. 
(11) For decades, the United States Agency for 
International Development has been a catalyst in the 
global health innovation ecosystem. While other Fed-
eral departments and agencies, including the Na-
tional Institutes of Health, the Centers for Disease 
Control and Prevention, and the Department of De-
fense, provide support for global health technologies, 
the United States Agency for International Develop-
ment is the only Federal agency that provides broad 
support for the late-stage development of new health 
technologies to combat neglected tropical diseases 
and emerging infectious diseases and other health 
conditions for low-resource settings specifically. 
(12) While the need for new tools to tackle dis-
ease threats has grown, in recent years, investments 
by the United States Agency for International De-
velopment in research and development have shrunk 
VerDate Sep 11 2014 
05:22 Nov 30, 2023
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6424.IH
H6424
SSpencer on DSK126QN23PROD with BILLS